Cancer is one of the leading causes of death worldwide. It is therefore not surprising it is responsible for the majority of clinical trials performed. Immune monitoring plays a big role in many of these clinical trials, especially in the earlier phases. Our scientific experts have a huge track record in the field of oncology and have implemented many immune monitoring techniques.

Study the tumor microenvironment by making use of our immunohistochemistry expertise and services that can provide you with multiplex immunohistochemistry panels up to 40 markers. Our cellular assays and extensive flow cytometry panels can make the difference for your immune monitoring goals. Antigen specific T cell analyses can be added to flow cytometry panels, studied with a proliferation dye or quantified using ELIspot or Fluorospot.

Have a look at our services or contact us for a custom made solution.

• (Spectral) Flow Cytometry
• Cellular assays
• Innate Immune Cells
• Killing Assays
• Mass Cytometry
• Metabolic pathway analysis
• Multiplex Immuno-histochemistry
• Proliferation assays

References

Bahce I, Dickhoff C, Schneiders FL, Veltman J, Heineman DJ, Hashemi SMS, Vrijmoet A, Houda I, Ulas EB, Bakker J, van de Ven P, Bouwhuis N, Meijboom LJ, Oprea-Lager DE, van Maldegem F, Fransen MF, de Gruijl TD, Radonic T, Senan S. Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study. J Immunother Cancer. 2024 Sep 30;12(9):e009799. doi: 10.1136/jitc-2024-009799. PMID: 39349061; PMCID: PMC11448277.

Michielon E, King LA, Waaijman T, Veth M, Spiekstra SW, van der Vliet HJ, Gibbs S, de Gruijl TD. An organotypic human melanoma-in-skin model as an in vitro tool for testing Vγ9Vδ2-T cell-based immunotherapy. Immunooncol Technol. 2024 Jul 10;24:100724. doi: 10.1016/j.iotech.2024.100724. PMID: 39220726; PMCID: PMC11363583.

Groen-van Schooten TS, Franco Fernandez R, van Grieken NCT, Bos EN, Seidel J, Saris J, Martínez-Ciarpaglini C, Fleitas TC, Thommen DS, de Gruijl TD, Grootjans J, Derks S. Mapping the complexity and diversity of tertiary lymphoid structures in primary and peritoneal metastatic gastric cancer. J Immunother Cancer. 2024 Jul 1;12(7):e009243. doi: 10.1136/jitc-2024-009243. PMID: 38955417; PMCID: PMC11218001.

de Haas AM, Stolk DA, Schetters STT, Goossens-Kruijssen L, Keuning E, Ambrosini M, Boon L, Kalay H, Storm G, van der Vliet HJ, de Gruijl TD, van Kooyk Y. Vaccination with DC-SIGN-Targeting αGC Liposomes Leads to Tumor Control, Irrespective of Suboptimally Activated T-Cells. Pharmaceutics. 2024 Apr 24;16(5):581. doi: 10.3390/pharmaceutics16050581. PMID: 38794243; PMCID: PMC11124829.

van den Ende T, Ezdoglian A, Baas LM, Bakker J, Lougheed SM, Harrasser M, Waasdorp C, van Berge Henegouwen MI, Hulshof MCCM, Haj Mohammad N, van Hillegersberg R, Mook S, van der Laken CJ, van Grieken NCT, Derks S, Bijlsma MF, van Laarhoven HWM, de Gruijl TD. Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition. Oncoimmunology. 2023 Jul 17;12(1):2233403. doi: 10.1080/2162402X.2023.2233403. PMID: 37470057; PMCID: PMC10353329.

Affandi AJ, Olesek K, Grabowska J, Nijen Twilhaar MK, Rodríguez E, Saris A, Zwart ES, Nossent EJ, Kalay H, de Kok M, Kazemier G, Stöckl J, van den Eertwegh AJM, de Gruijl TD, Garcia-Vallejo JJ, Storm G, van Kooyk Y, den Haan JMM. CD169 Defines Activated CD14+ Monocytes With Enhanced CD8+ T Cell Activation Capacity. Front Immunol. 2021 Jul 28;12:697840. doi: 10.3389/fimmu.2021.697840. PMID: 34394090; PMCID: PMC8356644.

Stolk DA, Horrevorts SK, Schetters STT, Kruijssen LJW, Duinkerken S, Keuning E, Ambrosini M, Kalay H, van de Ven R, Garcia-Vallejo JJ, de Gruijl TD, van Vliet SJ, van Kooyk Y. Palmitoylated antigens for the induction of anti-tumor CD8+ T cells and enhanced tumor recognition. Mol Ther Oncolytics. 2021 Apr 29;21:315-328. doi: 10.1016/j.omto.2021.04.009. PMID: 34141869; PMCID: PMC8170356.

Wang AZ, Brink HJ, Bouma RG, Affandi AJ, Nijen Twilhaar MK, Heijnen DAM, van Elk J, Maaskant JJ, Konijn VAL, Stolwijk JGC, Kalay H, Olesek K, van Kooyk Y, van der Schoot JMS, Bentlage AEH, Scheeren FA, Verdoes M, Vidarsson G, Kuijl CP, den Haan JMM. Development of a Versatile Cancer Vaccine Format Targeting Antigen-Presenting Cells Using Proximity-Based Sortase A-Mediated Ligation of T-Cell Epitopes. Bioconjug Chem. 2024 Nov 20;35(11):1805-1814. doi: 10.1021/acs.bioconjchem.4c00403. Epub 2024 Nov 7. PMID: 39511711; PMCID: PMC11583207.